NASDAQ:TCON - TRACON Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TRACON Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.73 -0.22 (-7.46 %) (As of 02/28/2020 01:24 PM ET) Add Compare Today's Range$2.60Now: $2.73▼$3.2050-Day Range$2.66MA: $3.79▼$4.4052-Week Range$2.07Now: $2.73▼$17.30Volume18,083 shsAverage Volume343,608 shsMarket Capitalization$8.57 millionP/E RatioN/ADividend YieldN/ABeta2.01 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCON Previous Symbol CUSIPN/A CIK1394319 Webhttp://www.traconpharma.com/ Phone858-550-0780Debt Debt-to-Equity Ratio0.84 Current Ratio1.58 Quick Ratio1.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3 million Price / Sales2.86 Cash FlowN/A Price / Cash FlowN/A Book Value$7.18 per share Price / Book0.38Profitability EPS (Most Recent Fiscal Year)($13.00) Net Income$-34,960,000.00 Net MarginsN/A Return on Equity-215.39% Return on Assets-85.47%Miscellaneous Employees26 Outstanding Shares3,140,000Market Cap$8.57 million Next Earnings Date5/12/2020 (Estimated) OptionableNot Optionable Receive TCON News and Ratings via Email Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TCON Rates by TradingView TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions What is TRACON Pharmaceuticals' stock symbol? TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON." How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($1.25) EPS for the quarter, topping the Zacks' consensus estimate of ($1.58) by $0.33. View TRACON Pharmaceuticals' Earnings History. When is TRACON Pharmaceuticals' next earnings date? TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 12th 2020. View Earnings Estimates for TRACON Pharmaceuticals. What price target have analysts set for TCON? 3 equities research analysts have issued twelve-month target prices for TRACON Pharmaceuticals' stock. Their forecasts range from $7.00 to $13.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 278.8% from the stock's current price. View Analyst Price Targets for TRACON Pharmaceuticals. What is the consensus analysts' recommendation for TRACON Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TRACON Pharmaceuticals. Has TRACON Pharmaceuticals been receiving favorable news coverage? News articles about TCON stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TRACON Pharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for TRACON Pharmaceuticals. Are investors shorting TRACON Pharmaceuticals? TRACON Pharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 129,300 shares, an increase of 81.3% from the January 30th total of 71,300 shares. Based on an average trading volume of 519,600 shares, the days-to-cover ratio is currently 0.2 days. Approximately 4.0% of the company's shares are short sold. View TRACON Pharmaceuticals' Current Options Chain. Who are some of TRACON Pharmaceuticals' key competitors? Some companies that are related to TRACON Pharmaceuticals include Polarityte (PTE), Organovo (ONVO), Entera Bio (ENTX), BioCardia (BCDA), Outlook Therapeutics (OTLK), Vical (VICL), aTyr Pharma (LIFE), CytRx (CYTR), Genetic Technologies (GENE), Titan Pharmaceuticals (TTNP), Aevi Genomic Medicine (GNMX), AIM ImmunoTech (AIM), TrovaGene (TROV), Enzon Pharmaceuticals (ENZN) and Vitro Diagnostics (VODG). What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include SCYNEXIS (SCYX), Verastem (VSTM), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Opko Health (OPK), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), MEI Pharma (MEIP), Progenics Pharmaceuticals (PGNX) and Catalyst Pharmaceuticals (CPRX). Who are TRACON Pharmaceuticals' key executives? TRACON Pharmaceuticals' management team includes the folowing people: Dr. Charles P. Theuer, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 55)Mr. Scott B. Brown, VP & Head of Fin.Dr. Sharon Real, Exec. VP of Product Devel. (Age 55)Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 42)Ms. Suzy Benedict, Sr. VP of Regulatory Affairs When did TRACON Pharmaceuticals IPO? (TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. Who are TRACON Pharmaceuticals' major shareholders? TRACON Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (11.04%), Renaissance Technologies LLC (4.83%) and Puissance Capital Management LP (2.42%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Cross-Border Opportu Puissance, Enterprise Associates 14 New and Mark C Wiggins. View Institutional Ownership Trends for TRACON Pharmaceuticals. Which institutional investors are selling TRACON Pharmaceuticals stock? TCON stock was sold by a variety of institutional investors in the last quarter, including Puissance Capital Management LP, NEA Management Company LLC and Renaissance Technologies LLC. View Insider Buying and Selling for TRACON Pharmaceuticals. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is TRACON Pharmaceuticals' stock price today? One share of TCON stock can currently be purchased for approximately $2.64. How big of a company is TRACON Pharmaceuticals? TRACON Pharmaceuticals has a market capitalization of $8.29 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-34,960,000.00 in net income (profit) each year or ($13.00) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe.View Additional Information About TRACON Pharmaceuticals. What is TRACON Pharmaceuticals' official website? The official website for TRACON Pharmaceuticals is http://www.traconpharma.com/. How can I contact TRACON Pharmaceuticals? TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected] MarketBeat Community Rating for TRACON Pharmaceuticals (NASDAQ TCON)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 228 (Vote Outperform)Underperform Votes: 183 (Vote Underperform)Total Votes: 411MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: Dividend Reinvestment Plan (DRIP)
